BR9607846B1 - métodos de seleção de agentes que modulam ou inibem associação de tau-tau, ou revertem toxicidade na célula de tau agregado. - Google Patents

métodos de seleção de agentes que modulam ou inibem associação de tau-tau, ou revertem toxicidade na célula de tau agregado.

Info

Publication number
BR9607846B1
BR9607846B1 BRPI9607846-4A BR9607846A BR9607846B1 BR 9607846 B1 BR9607846 B1 BR 9607846B1 BR 9607846 A BR9607846 A BR 9607846A BR 9607846 B1 BR9607846 B1 BR 9607846B1
Authority
BR
Brazil
Prior art keywords
tau
methods
disease
modulate
association
Prior art date
Application number
BRPI9607846-4A
Other languages
English (en)
Portuguese (pt)
Other versions
BR9607846A (pt
Inventor
Claude Michel Wischik
Patricia Carol Edwards
Charles Robert Harrington
Martin Roth
Aaron Klug
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10771951&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9607846(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of BR9607846A publication Critical patent/BR9607846A/pt
Publication of BR9607846B1 publication Critical patent/BR9607846B1/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
BRPI9607846-4A 1995-03-27 1996-03-25 métodos de seleção de agentes que modulam ou inibem associação de tau-tau, ou revertem toxicidade na célula de tau agregado. BR9607846B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9506197.4A GB9506197D0 (en) 1995-03-27 1995-03-27 Inhibition of tau-tau association.
PCT/EP1996/001307 WO1996030766A1 (en) 1995-03-27 1996-03-25 Inhibition of tau-tau-association

Publications (2)

Publication Number Publication Date
BR9607846A BR9607846A (pt) 1998-07-14
BR9607846B1 true BR9607846B1 (pt) 2009-05-05

Family

ID=10771951

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9607846-4A BR9607846B1 (pt) 1995-03-27 1996-03-25 métodos de seleção de agentes que modulam ou inibem associação de tau-tau, ou revertem toxicidade na célula de tau agregado.

Country Status (17)

Country Link
US (5) US6376205B1 (de)
EP (2) EP1067386B1 (de)
JP (1) JP3612078B2 (de)
CN (3) CN100406892C (de)
AT (2) ATE470860T1 (de)
AU (1) AU5334496A (de)
BR (1) BR9607846B1 (de)
CA (2) CA2215397C (de)
DE (2) DE69638197D1 (de)
DK (2) DK1067386T3 (de)
ES (2) ES2346284T3 (de)
GB (1) GB9506197D0 (de)
HK (1) HK1068950A1 (de)
MX (1) MX9706902A (de)
PT (2) PT1067386E (de)
TR (1) TR199701039T1 (de)
WO (1) WO1996030766A1 (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
AU744881B2 (en) * 1997-09-04 2002-03-07 Board Of Trustees Of The Leland Stanford Junior University Assays for detecting modulators of cytoskeletal function
US7252950B1 (en) 1997-09-04 2007-08-07 The Regents Of The University Of California Assays for detecting modulators of cytoskeletal function
CN1100787C (zh) * 1998-05-08 2003-02-05 北京大学 新型血吸虫疫苗肽
ATE326700T1 (de) * 1999-09-09 2006-06-15 Max Planck Gesellschaft SCREENING NACH INHIBITOREN VON ßGEPAARTEN HELIKALEN FILAMENTENß
GB0017060D0 (en) * 2000-07-11 2000-08-30 Hunter Fleming Ltd Production, stabilisation and use of reduced forms of pharmaceutical compounds
CA2357450A1 (en) * 2000-09-29 2002-03-29 Warner-Lambert Company Phenoxazine analogs useful as amyloid aggregation inhibitors and treatment of alzheimer's disease and disorders related to amyloidosis
GB0100119D0 (en) 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
AU2007200212B2 (en) * 2001-01-15 2010-08-26 Wista Laboratories Ltd. Materials and methods relating to protein aggregation in neurodegenerative disease
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
GB0113121D0 (en) 2001-05-30 2001-07-18 Univ Leeds Biologically active photosensitisers
GB0117326D0 (en) 2001-07-16 2001-09-05 Univ Aberdeen Napthoquinone-type inhibitors of protein aggregation
US20050079526A1 (en) * 2002-02-20 2005-04-14 Affinium Pharmaceuticals, Inc. Methods and apparatuses for characterizing refolding and aggregation of biological molecules
AU2003220222A1 (en) * 2002-03-13 2003-09-29 Signum Biosciences, Inc. Modulation of protein methylation and phosphoprotein phosphate
DK1521774T3 (da) * 2002-07-12 2008-10-27 Axon Neuroscience Trunkerede Tau-proteiner
US7172875B2 (en) * 2003-02-18 2007-02-06 The Ohio State University Research Foundation Identifying inhibitors of intracellular protein fibrillization
MXPA06001891A (es) * 2003-08-18 2006-05-17 Novartis Ag Derivados de 3h-fenoxazina adecuados como agentes para la formacion de imagenes casi-infrarrojas, preparacion y uso de los mismos.
US7238788B2 (en) * 2004-02-18 2007-07-03 University Of Iowa Foundation Antibodies to phosphorylated tau, methods of making and methods of use
CN101084204B (zh) 2004-09-23 2012-12-05 卫思道制药有限公司 包括亚甲蓝(mtc)在内的二氨基吩噻嗪鎓化合物的化学合成和纯化方法
PL2322517T3 (pl) 2004-09-23 2019-09-30 Wista Laboratories Ltd. Sposoby syntezy chemicznej i oczyszczania związków diaminofenotiazyniowych, w tym chlorku metylotioniny (MTC)
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
CA2601777A1 (en) * 2005-02-03 2006-08-10 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US20060188866A1 (en) * 2005-02-18 2006-08-24 Children's Hospital Oakland Research Institute Diaminophenothiazine compositions and uses thereof
AU2013200732B2 (en) * 2006-03-29 2015-04-09 Wista Laboratories Ltd. 3,7-diamino-10H-phenothiazine salts and their use
EP2853293B1 (de) * 2006-03-29 2017-11-22 WisTa Laboratories Ltd. Thioniniumverbindungen und deren Verwendung
PT2013191E (pt) 2006-03-29 2010-10-29 Wista Lab Ltd Sais de 3,7-diamino-10h-fenotiazina e a sua utilização
AU2007231126B2 (en) 2006-03-29 2012-11-01 Wista Laboratories Ltd. Inhibitors of protein aggregation
ES2912571T3 (es) 2006-07-11 2022-05-26 Wista Lab Ltd Procedimientos de síntesis y/o de purificación de compuestos de diaminofenotiazinio
US20110263696A1 (en) * 2007-03-30 2011-10-27 Graves Donald J Proanthocyanidins from cinnamon and its water soluble extract inhibit tau aggregation
PT2167095T (pt) * 2007-06-19 2019-08-06 Wista Lab Ltd Compostos de fenotiazina para o tratamento de comprometimento cognitivo leve
PL2205245T3 (pl) 2007-10-03 2015-12-31 Wista Lab Ltd Zastosowanie terapeutyczne diaminofenotiazyn
EP2090166A1 (de) * 2008-02-14 2009-08-19 Bayer CropScience AG Flüssige herbizide Zubereitungen
US8715643B2 (en) 2008-04-09 2014-05-06 Tokyo Metropolitan Institute Of Medical Science TDP-43-storing cell model
ES2600278T3 (es) 2008-12-10 2017-02-08 Wista Laboratories Ltd. Sales de xantilio 3,6-disustituidas como medicamentos
UA107571C2 (xx) * 2009-04-03 2015-01-26 Фармацевтична композиція
PL2430007T3 (pl) 2009-05-12 2014-07-31 Wista Lab Ltd Sposoby chemicznej syntezy związków diaminofenotiazyniowych z zastosowaniem nadsiarczanowych środków utleniających
WO2011017319A1 (en) 2009-08-03 2011-02-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of treating disorders associated with protein polymerization
EP2480891B1 (de) * 2009-09-24 2016-11-23 INSERM - Institut National de la Santé et de la Recherche Médicale Fkbp52-tau-interaktion als neuartiges therapeutisches target zur behandlung von neurologischen erkrankungen im zusammenhang mit tau-störungen
DK3792254T3 (da) 2009-09-24 2023-09-25 Wista Lab Ltd Krystallinske methylthioninium-chloridhydrater
US8809617B2 (en) 2009-11-05 2014-08-19 The University of Pittsburgh—Of the Commonwealth System of Higher Education Automated high-content live animal drug screening using C. elegans
US9072772B2 (en) 2009-11-05 2015-07-07 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating disorders associated with protein aggregation
WO2011056222A1 (en) * 2009-11-05 2011-05-12 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of treating disorders associated with protein aggregation
US8796448B1 (en) * 2010-12-09 2014-08-05 Prosetta Antiviral Inc. Compounds, compositions, and methods for treating Alzheimer's disease
EP2645994B1 (de) 2010-11-30 2017-11-01 WisTa Laboratories Ltd. Formulierungen enthaltend methylthioninium chlorid
DK2835131T3 (en) 2010-12-14 2017-12-04 Electrophoretics Ltd Casein kinase 1 delta inhibitors (CK1 delta)
EP2670434B1 (de) * 2011-01-31 2018-12-26 Tau Bio-Logic Corp. Behandlung von tauopathien
US9283230B2 (en) 2011-02-11 2016-03-15 Wista Laboratories Ltd. Phenothiazine diaminium salts and their use
US8349376B1 (en) * 2011-03-08 2013-01-08 Bezzek Mark S Anti-dementia regimen
US8846061B1 (en) 2011-03-08 2014-09-30 Mark S. Bezzek Multivitamin-mineral regimens for longevity and wellness
WO2012162179A1 (en) * 2011-05-20 2012-11-29 Oligomerix, Inc. Tau protease compositions and methods of use
US8980884B2 (en) 2011-06-01 2015-03-17 Wisconsin Alumni Research Foundation Methods for treating Alzheimer's disease
GB201111361D0 (en) * 2011-07-04 2011-08-17 Nordic Bioscience As Biochemical markers for neurodegenerative conditions
HUE036177T2 (hu) 2011-09-19 2018-06-28 Axon Neuroscience Se TAU-mediált patológia protein alapú terápiája és diagnózisa Alzheimer-betegségben
SG11201406347TA (en) 2012-04-05 2014-11-27 Ac Immune Sa Humanized tau antibody
WO2014150877A2 (en) 2013-03-15 2014-09-25 Ac Immune S.A. Anti-tau antibodies and methods of use
GB201317702D0 (en) 2013-10-07 2013-11-20 Wista Lab Ltd Methods of chemical synthesis of diaminophenothiazinium compounds including methylthioninium chloride (MTC)
US10765755B1 (en) 2013-11-20 2020-09-08 University Of South Florida Preparation and characterization of methylene blue nanoparticles for Alzheimer's disease and other tauopathies
JP6370674B2 (ja) * 2014-10-22 2018-08-08 国立研究開発法人国立長寿医療研究センター タウオパチー治療薬およびそのスクリーニング方法
AU2016215155A1 (en) * 2015-02-04 2017-08-17 F. Hoffmann-La Roche Ag Tau antisense oligomers and uses thereof
KR101722930B1 (ko) * 2015-06-19 2017-04-04 한국과학기술연구원 전이성 타우 단백질 및 이의 제조 방법
GB201512678D0 (en) 2015-07-20 2015-08-26 Wista Lab Ltd Methods of chemical synthesis
KR102475825B1 (ko) 2016-07-25 2022-12-08 위스타 레보레이토리스 리미티드 디아미노페노티아진 (diaminophenothiazines)의 투여 및 투여량 (dosage)
GB201614834D0 (en) 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
GB201621817D0 (en) 2016-12-21 2017-02-01 Wista Lab Ltd Methods of chemical synthesis
CN111094327A (zh) * 2017-08-16 2020-05-01 Lgv1有限公司 Bpifb4蛋白的用于神经元疾病和损伤的vtft同种型
EP4364801A2 (de) 2018-07-26 2024-05-08 WisTa Laboratories Ltd. Optimierte dosierung von diaminophenothiazinen in populationen
US11155609B2 (en) 2019-04-05 2021-10-26 TauC3 Biologies Limited Anti-TAUC3 antibodies and uses thereof
GB202010652D0 (en) 2020-07-10 2020-08-26 Wista Lab Ltd Anti-tau antibodies
GB202010620D0 (en) 2020-07-10 2020-08-26 Wista Lab Ltd System
WO2023232764A1 (en) 2022-05-31 2023-12-07 Wista Laboratories Ltd. Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds
GB202213796D0 (en) 2022-09-21 2022-11-02 Wista Lab Ltd Tau aggregation inhibitors
WO2024061971A1 (en) 2022-09-21 2024-03-28 Wista Laboratories Ltd. Novel formulations and vehicles

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US391675A (en) * 1888-10-23 Rack for exhibiting hose or other goods
BE569430A (de) * 1957-07-17
GB8724412D0 (en) 1987-10-19 1987-11-25 Medical Res Council Protein
US5571666A (en) * 1988-10-28 1996-11-05 Oklahoma Medical Research Foundation Thiazine dyes used to inactivate HIV in biological fluids
JPH0833127B2 (ja) * 1990-05-01 1996-03-29 株式会社ユニシアジェックス 内燃機関の空燃比制御装置
JPH0725786A (ja) 1990-05-16 1995-01-27 Univ Rockefeller アルツハイマー病を伴うアミロイドーシスの治療
WO1993001348A1 (en) 1991-07-10 1993-01-21 Minnesota Mining And Manufacturing Company Fluorochemical water- and oil- repellent treating compositions
WO1993003369A1 (en) 1991-08-01 1993-02-18 Voorheis Paul H Diagnostic method for alzheimer's disease
WO1993003177A1 (en) 1991-08-09 1993-02-18 Massachusetts Institute Of Technology Novel tau/neurofilament protein kinases
DK0618968T3 (da) 1991-12-06 2000-04-10 Max Planck Gesellschaft Midler til diagnostisering og behandling af Alzheimer's sygdom
GB9316727D0 (en) * 1993-08-12 1993-09-29 Inst Of Psychiatry Models of alzheimers's disease
GB9317193D0 (en) 1993-08-18 1993-10-06 Zeneca Ltd Method
EP0778773A1 (de) 1994-08-08 1997-06-18 Albert Einstein College Of Medicine Of Yeshiva University Verfahren zur behandlung und/oder vorbeugung von alzheimer'sche krankheit mit phenothiazine und/oder thioxanthene
DE4430091A1 (de) * 1994-08-25 1996-02-29 Bayer Ag Verwendung von N-substituierten Phenothiazinen
GB9506197D0 (en) * 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
US5804601A (en) 1995-04-10 1998-09-08 Takeda Chemical Industries, Ltd. Aromatic hydroxamic acid compounds, their production and use
US6953675B2 (en) * 1997-11-06 2005-10-11 Immunomedics, Inc. Landscaped antibodies and antibody fragments for clinical use
WO1999062548A1 (en) 1998-06-01 1999-12-09 Advanced Research And Technology Institute Methods and compositions for diagnosing tauopathies
FR2788436A1 (fr) 1999-01-14 2000-07-21 Pf Medicament Composition d'un derive de phenothiazine
WO2001053340A2 (en) 2000-01-21 2001-07-26 Pharmacia & Upjohn Company Transgenic mouse model of human neurodegenerative disease
GB0100119D0 (en) 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
GB0117326D0 (en) 2001-07-16 2001-09-05 Univ Aberdeen Napthoquinone-type inhibitors of protein aggregation
US6953974B2 (en) * 2003-08-26 2005-10-11 Texas Instruments Incorporated EEPROM device and method for providing lower programming voltage
GB0322756D0 (en) 2003-09-29 2003-10-29 Univ Aberdeen Methods of chemical synthesis
US7939538B2 (en) 2004-06-28 2011-05-10 Amgen Inc. Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases
WO2006030676A1 (ja) 2004-09-14 2006-03-23 Denki Kagaku Kogyo Kabushiki Kaisha アルミニウム－炭化珪素質複合体
PL2322517T3 (pl) 2004-09-23 2019-09-30 Wista Laboratories Ltd. Sposoby syntezy chemicznej i oczyszczania związków diaminofenotiazyniowych, w tym chlorku metylotioniny (MTC)

Also Published As

Publication number Publication date
TR199701039T1 (xx) 1998-02-21
US20070191352A1 (en) 2007-08-16
WO1996030766A1 (en) 1996-10-03
US20020168687A1 (en) 2002-11-14
DK1067386T3 (da) 2010-10-04
EP1067386A3 (de) 2004-11-24
US20060014216A1 (en) 2006-01-19
ES2346284T3 (es) 2010-10-14
PT1067386E (pt) 2010-08-31
PT817969E (pt) 2002-12-31
CN100406892C (zh) 2008-07-30
CN1935143A (zh) 2007-03-28
ATE470860T1 (de) 2010-06-15
EP1067386A2 (de) 2001-01-10
EP0817969B1 (de) 2002-07-31
DE69622701D1 (de) 2002-09-05
JP3612078B2 (ja) 2005-01-19
DE69622701T2 (de) 2003-03-06
US6376205B1 (en) 2002-04-23
CA2633573A1 (en) 1996-10-03
CN1179829A (zh) 1998-04-22
ES2180753T3 (es) 2003-02-16
BR9607846A (pt) 1998-07-14
US6953794B2 (en) 2005-10-11
ATE221662T1 (de) 2002-08-15
CN1150404C (zh) 2004-05-19
GB9506197D0 (en) 1995-05-17
CA2215397C (en) 2008-12-02
CA2215397A1 (en) 1996-10-03
EP1067386B1 (de) 2010-06-09
DK0817969T3 (da) 2002-11-25
US7534786B2 (en) 2009-05-19
US20080207604A1 (en) 2008-08-28
DE69638197D1 (de) 2010-07-22
AU5334496A (en) 1996-10-16
JPH11502925A (ja) 1999-03-09
US8278298B2 (en) 2012-10-02
HK1068950A1 (en) 2005-05-06
CN1544945A (zh) 2004-11-10
MX9706902A (es) 1997-11-29
EP0817969A1 (de) 1998-01-14
CA2633573C (en) 2010-09-14

Similar Documents

Publication Publication Date Title
BR9607846B1 (pt) métodos de seleção de agentes que modulam ou inibem associação de tau-tau, ou revertem toxicidade na célula de tau agregado.
AU8692391A (en) Improvements in or relating to organic compounds
DE69408032D1 (de) Vorrichtung zur Verminderung des Laufgeräusches von Fahrzeugen
DE69113712T2 (de) Einrichtung zur Bestimmung des Abnutzungszustandes von Fahrzeugluftreifen.
BR9910044A (pt) Composição alimentìcia e seu processo de uso
ATE209490T1 (de) Substanz p antagonisten zur behandlung von erbrechen
PL322333A1 (en) Dna encoding human papilloma viruses of type 18
DE69700308T2 (de) Kovalentgebundene Dimere von Glykopeptid-Antibiotika
KR890014394A (ko) 탈수오니케이크의 소취방법
DE9312198U1 (de) Anordnung zur Reduzierung des Feuchtegehalts von Bioschlamm
BR0009675A (pt) Métodos adequado para tipificar prpsc e de alterar a conformação de prpsc, uso de um agente capaz de afetar a ligação de prpsc a um ou mais ìons metálicos divalentes, métodos de triar para um agente capaz de alterar a conformação do prpsc tipo 1 e/ou tipo 2 e de triar para um agente para uso na prevenção diagnóstico e/ou tratamento de uma doença de prion, uso de um agente obtenìvel por um método, kit, prpsc isolado tipo 2, e, uso de prpsc isolado tipo 2
IL97308A0 (en) 6-substituted-hexahydrobenz(cd)indoles
DE59602836D1 (de) Reinigung von Gewebefaktor
DE69321893T2 (de) Verfahren zum Nachweis von Alzheimer-Krankheit
Nammalwar Biochemical changes resulting from bioassay of heavy metals mercury and cadmium to the grey mullet Liza macrolepis(Smith).
BR9900024A (pt) Biciclo[3.1.0]hexanos e compostos relacionados.
DE59004227D1 (de) Vorrichtung zur Neigungskompensation des Aufbaus von Kraftfahrzeugen.
ITTO910913A1 (it) Macchina di tornitura dei ceppi di freni di autoveicoli e calibro di regolazione della profondita' di passata del suo utensile.
FI101548B1 (fi) Menetelmä ja laite karheemisessa
IT1236393B (it) Sistema di pedale multipotenza da grancassa per batteria

Legal Events

Date Code Title Description
PC Transfer

Free format text: THE UIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB)

FB36 Technical and formal requirements: requirement - article 36 of industrial property law
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: WISTA LABORATORIES LTD. (SG)

Free format text: TRANSFERIDO DE: THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 28/07/2009, OBSERVADAS AS CONDICOES LEGAIS.

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI-52400.061589/2013 ORIGEM: JUIZO DA 013A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO 0132279-24.2013.4.02.5101 ACAO DE NULIDADE DAS PATENTES SUBMETIDAS AO MAILBOX (ART. 229, PARAGRAFO UNICO DA LPI); ALTERNATIVAMENTE, A DECRETACAO DA NULIDADE PARCIAL PARA CORRECAO DO PRAZO DE VIGENCIA; SUBSIDIARIAMENTE, CASO SE ENTENDA NAO SER O CASO DE NULIDADE, A CORRECAO DO ATO ADMINISTRATIVO PARA ADEQUACAO DA VIGENCIA DAS PATENTES. AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI REU: WARSAW ORTHOPEDIC, WISTA LABORATORIES, WYETH, WYETH HOLDINGS CORPORATION.

B21B Extinction acc. art. 78, item ii - on waiver by the patentee, without prejudice to the rights of third parties

Free format text: SOLICITADA ATRAVES DA PETICAO 860130005431, DE 23/10/2013